Dermatitis

Once-daily crisaborole ointment 2% may be an effective and well-tolerated long-term maintenance therapy for pediatric and adult patients with mild to moderate atopic dermatitis, according to a study.

Alphyn Biologics announced new data from its phase 2a clinical trial evaluating topical AB-101a for the treatment of mild to moderate atopic dermatitis in patients aged as young as 2 years, according to a company release.

Patients taking lebrikizumab for the treatment of moderate to severe atopic dermatitis maintained similar responses regardless of dose frequency, according to results presented at 25th World Congress of Dermatology in Singapore.

In this Healio video exclusive, George Martin, MD, discusses highlights from Maui Derm NP+PA, including the use of oral and topical JAK inhibitors to treat atopic dermatitis.

An increased rate of venous thromboembolism is associated with atopic dermatitis in adults, although that increased risk is small, according to a study.

The quality and quantity of ultraviolet B phototherapy sessions for the treatment of atopic dermatitis did not increase the risk of skin cancer development in patients, according to a study.

Mindfulness and self-compassion training may be an effective treatment option to increase the quality of life for adults with atopic dermatitis, according to data published in JAMA Dermatology.

Once-daily roflumilast foam 0.3% demonstrated safety and efficacy in the treatment of erythema, scaling and itching caused by seborrheic dermatitis, according to a phase 2a study.

New data from a phase 2 study evaluating the short-term clinical benefits of Opzelura cream 1.5% showed a reduction in itch among adults with mild to moderate atopic dermatitis, Incyte announced in a press release.

Tralokinumab at doses of 150 mg or 300 mg was associated with improvements over placebo in a number of efficacy outcomes at 16 weeks and 52 weeks in adolescents with moderate to severe atopic dermatitis, according to a study.